Leerink Partnrs Increases Earnings Estimates for AstraZeneca

AstraZeneca PLC (NASDAQ:AZN) – Research analysts at Leerink Partnrs boosted their Q4 2025 EPS estimates for shares of AstraZeneca in a research note issued on Sunday, November 9th. Leerink Partnrs analyst A. Berens now anticipates that the company will post earnings per share of $1.18 for the quarter, up from their prior estimate of $1.11. The consensus estimate for AstraZeneca’s current full-year earnings is $4.51 per share.

Other equities analysts also recently issued research reports about the company. Jefferies Financial Group assumed coverage on AstraZeneca in a report on Monday, October 27th. They issued a “buy” rating on the stock. Deutsche Bank Aktiengesellschaft cut AstraZeneca from a “hold” rating to a “sell” rating in a research report on Thursday, October 16th. Finally, Weiss Ratings reiterated a “buy (b)” rating on shares of AstraZeneca in a research note on Wednesday, October 8th. Five research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $86.00.

AstraZeneca Stock Performance

Shares of AZN opened at $89.09 on Wednesday. The company has a debt-to-equity ratio of 0.55, a current ratio of 0.86 and a quick ratio of 0.67. The stock has a market cap of $276.30 billion, a price-to-earnings ratio of 33.49, a PEG ratio of 1.52 and a beta of 0.34. AstraZeneca has a one year low of $61.24 and a one year high of $89.32. The company has a 50-day moving average of $81.73 and a two-hundred day moving average of $75.87.

AstraZeneca (NASDAQ:AZN) last issued its quarterly earnings data on Thursday, November 6th. The company reported $1.19 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.14 by $0.05. AstraZeneca had a return on equity of 32.84% and a net margin of 14.68%.The business had revenue of $15.19 billion during the quarter, compared to analyst estimates of $14.75 billion. During the same period in the prior year, the company posted $2.08 EPS. The business’s revenue for the quarter was up 12.0% compared to the same quarter last year.

Institutional Trading of AstraZeneca

Institutional investors and hedge funds have recently bought and sold shares of the stock. NewSquare Capital LLC increased its position in AstraZeneca by 149.3% during the second quarter. NewSquare Capital LLC now owns 364 shares of the company’s stock worth $25,000 after buying an additional 218 shares during the last quarter. Larson Financial Group LLC grew its position in shares of AstraZeneca by 297.9% during the 1st quarter. Larson Financial Group LLC now owns 386 shares of the company’s stock worth $28,000 after purchasing an additional 289 shares in the last quarter. Richardson Financial Services Inc. raised its holdings in AstraZeneca by 59.8% in the 2nd quarter. Richardson Financial Services Inc. now owns 398 shares of the company’s stock valued at $28,000 after acquiring an additional 149 shares in the last quarter. Costello Asset Management INC acquired a new stake in AstraZeneca during the first quarter worth about $29,000. Finally, Rakuten Investment Management Inc. bought a new stake in AstraZeneca during the third quarter worth $31,000. Institutional investors own 20.35% of the company’s stock.

AstraZeneca Company Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.